1 / 25
Murakami Lab, May 2025
2 / 25
Nina Xiong and Taiyang Chen presenting “Access to Diagnosis through Liquid Biopsy (ADLiB): expediting lymphoma diagnosis in a high-need setting” at the Hematologic Neoplasia & Immunologic Therapies Seminar, May 2025
3 / 25
Chase Weizer presenting his poster at 2025 AACR in Chicago, IL
4 / 25
Last week in the lab for summer students Rahaf and Sophie ☹, August 2025 (Left to right: Rahaf Qarabsa, Sophie Zhu, Alyssa Wu, Claire Walter, Emily Sumpena)
5 / 25
Emily Sumpena smiling her way through tissue culture work, August 2025
6 / 25
Luzany Correia presenting his work at the End of Summer CURE Presentation, August 2025
7 / 25
End of Summer CURE Presentation by Ashreen Williams, August 2025
8 / 25
Nina Xiong working on ADLiB!
9 / 25
Rahaf Qarabsa getting down to business, August 2025
10 / 25
Lab outing to Island Creek Oyster Farm, June 2025
11 / 25
Oyster shucking at Island Creek Oyster Farm, June 2025
12 / 25
Alyssa Wu locking in, August 2025
13 / 25
Dr. Mark Murakami presenting “Ph+ Acute Lymphoblastic Leukemia: Dual TKI Therapy and Pathways of Resistance” at Hematologic Neoplasia & Immunologic Therapies Seminar, May 2025
14 / 25
Lunch with the Parry Lab, May 2025
15 / 25
Goodbye, Nina ☹ (we miss you!)
16 / 25
Claire Walter showing Rahaf Qarabsa how to process primary samples, August 2025
17 / 25
Murakami Lab, December 2024
18 / 25
Congratulations to Taiyang Chen on her excellent capstone presentation for the HMS Biomedical Informatics Master's Program in December 2024! (Left to right: Nina Xiong, Taiyang Chen, Mark Murakami)
19 / 25
Dr. Mark Murakami, Dr. Katherine Antel, Dr. Lydie Debaize, and Dr. Mingzeng Zhang (clockwise) grabbing lunch at 2023 AACR in Orlando, FL!
20 / 25
Murakami Lab, Summer 2023
21 / 25
Going away for Dr. Katherine Antel ☹, September 2023
22 / 25
Lunch with the Pikman Lab, June 2023
23 / 25
Summer outing in Fenway, July 2022
24 / 25
Lab lunch in Fenway, July 2022
25 / 25
End of Summer CURE Presentation by Mia Blennau, August 2022

About

The Murakami Lab at DFCI studies minimal residual disease in B-cell leukemia and lymphoma and aims to translate mechanistic discoveries into individualized therapies to improve patient outcomes by utilizing our repository of preclinical models including patient-derived xenograft (PDX) mouse models, access to conventional and experimental therapeutic agents, expertise in lymphoid genomics and bioinformatics, novel single-cell biophysical and molecular profiling platforms, and involvement in early phase clinical trials.